Canada markets closed

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
58.80+3.82 (+6.95%)
At close: 4:00PM EDT

ChemoCentryx, Inc.

850 Maude Avenue
Mountain View, CA 94043
United States
650 210 2900
http://www.chemocentryx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees82

Key Executives

NameTitlePayExercisedYear Born
Dr. Thomas J. Schall Ph.D.Founder, Pres, CEO & Chairman968.76k8.42M1959
Ms. Susan M. KanayaExec. VP, Chief Financial & Admin. Officer and Sec.696.65k10.18M1963
Dr. Markus J. CappelSr. VP, Chief Bus. Officer & Treasurer563.8k7.43M1961
Ms. Kari E. LeetchSr. VP of HRN/AN/AN/A
Dr. Catherine Lee KelleherSr. VP of Clinical Devel.N/AN/AN/A
Ms. Dalia R. RayesSr. VP & Head of CommercialN/AN/AN/A
Dr. Sangita Ghosh Ph.D.Sr. VP of Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.

Corporate Governance

ChemoCentryx, Inc.’s ISS Governance QualityScore as of October 6, 2020 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.